Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01896843 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain
A Phase 1 study of mGluR5 Receptors, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
- 1
- Study location
NCT01896843 is a Phase 1 study of mGluR5 Receptors that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 19 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01896843, a Phase 1 study of mGluR5 Receptors, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: \- A small brain protein called the metabotropic glutamate receptor subtype 5 (mGluR5) may affect several brain diseases such as autism and depression. Researchers will use 2 radioactive chemicals (\[11C\]SP203 and \[11C\]FPEB) and a research drug (STX107) that can attach to the receptor, to figure out the best way to use positron emission tomography (PET) to see the mGluR5 receptor. They will use scans to monitor where the radioactivity goes. Objectives: \- To find the best way to image the mGluR5 receptor in the brain. Eligibility: \- Healthy volunteers ages 18 to 55. Design: * All participants will be screened with a medical exam at visit 1. In later visits, they may have a PET scan, when two small tubes are placed under the skin and they lie down in a scanner. They may have an MRI scan, when they lie down in a scanner. * Part 1 participants will have 2 more visits. They will have a PET brain scan using \[11C\]FPEB and will have blood drawn. Then they will have an MRI brain scan. * Part 2 participants will have 1 more visit, with a whole body PET scan using \[11C\]FPEB and blood drawn. * Part 3 participants will have 4 more visits, including 1 overnight stay at a hospital. Over all the visits, they will have 4 PET scans and 1 MRI brain scan. They will receive the research drug and injections of both chemicals. Blood will be drawn during the scans.
Conditions Studied
Interventions
- DRUG STX107
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2013-06-27 |
| Est. Completion | 2016-06-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01896843
The ClinicalTrials.gov registry entry for NCT01896843 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with mGluR5 Receptors appearing as the primary indexed condition, and to 1 intervention - of which STX107 is the first listed.
NCT01896843 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT01896843 about?
NCT01896843 is a clinical study titled "Evaluation of Two Radioactive Chemicals to Image mGluR5 Receptors in Brain". Background: \- A small brain protein called the metabotropic glutamate receptor subtype 5 (mGluR5) may affect several brain diseases such as autism and depression. Researchers will use 2 radioactive chemicals (\[11C\]SP203 and \[11C\]FPEB) and a research drug (STX107) that can attach to the recepto...
What is the current status of trial NCT01896843?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2013-06-27. Estimated completion is 2016-06-16.
What conditions does trial NCT01896843 study?
This clinical trial studies the following conditions: mGluR5 Receptors.
What interventions are being tested in trial NCT01896843?
The interventions under investigation include: STX107 (DRUG).
Who is sponsoring clinical trial NCT01896843?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01896843 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.